AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 81 min read$TEVA

Francis Richard D sold $211K of TEVA

Francis Richard D (President and CEO) sold 6,153 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $34.35 ($0.21M total) on 2026-06-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Francis Richard D
Published Jun 8, 2026, 8:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 8, 2026, 8:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TEVA
Neutral
medium confidence
Mentioned
$TEVA
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEVANeutralLow
01

Why it matters

This provides a fresh, auditable datapoint on insider activity, but the 10b5-1 designation typically limits inference about near-term fundamentals.

02

Market read

A new insider-selling datapoint for TEVA, likely to have only marginal trading impact absent other catalysts.

03

What to watch

Traders may overreact to insider selling; without accompanying operational/regulatory news, the signal is usually weak.

Relevance 3/10Novelty 6/10Timing: filed June 8, covering a June 5 sale

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for TEVA, detailing an officer’s open-market sale under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$TEVANeutralMedium confidence
Context

SEC Form 4 shows TEVA CEO Francis Richard D sold 6,153 shares for ~$211.4K on a Rule 10b5-1 plan (open-market sale).

Expected impact

Low likelihood of a sustained price move solely from this disclosure; any reaction is likely brief unless accompanied by other catalysts.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit Rule 10b5-1 pre-arrangement, which reduces interpretive weight versus discretionary selling.

Market effects

Sector

No direct sector read-across; this is company-specific insider transaction disclosure.

Regional

None indicated beyond potential minor sentiment in US-listed TEVA.

Global

None indicated; transaction is not tied to global operational developments in the text.

Counterpoint

What could challenge this read

Because the sale is explicitly under a Rule 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • issuer
    TEVA

    TEVA Pharmaceutical Industries Ltd; subject of the Form 4 insider sale disclosure.

  • insider
    Francis Richard D

    President and CEO; reported the sale of 6,153 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TEVA insider trading history →

Related articles

SEP 4
$TEVAMed

S&P upgrades Teva rating on deleveraging and pipeline strength

S&P Global Ratings upgraded Teva Pharmaceutical Industries Ltd. to 'BBB-' from 'BB+', citing strong branded products, generics stabilization, and debt reduction. Teva's key brands generated $3.1B in 2025, with expected growth. The company reduced debt from $29B in 2018 to $17B in 2025 and aims for mid-3x leverage by year-end. S&P forecasts strong cash flow and debt reduction.

investing.com2 min
SEP 4
$TEVAMed

Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

Teva Pharmaceuticals (TEVA) agreed to a stalking-horse bid of up to $125M for BioXcel Therapeutics' (BTAI) assets, including $57.5M in cash and up to $67.5M in contingent payments. The deal, subject to court approval, includes IGALMI and other assets. The FDA has a 2026 target date for a supplemental application to expand IGALMI's label to at-home use. Competing bids may arise.

finance.yahoo.com3 min
SEP 4
$TEVAMed

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

S&P Global Ratings upgraded Teva Pharmaceutical's long-term issuer credit rating to BBB- from BB+, reflecting strong financial performance and debt reduction. This is the third upgrade in recent months, with Teva now holding investment-grade ratings from all major agencies. The company's CFO attributed the upgrades to successful execution of its growth strategy and improved financial profile.

globenewswire.com1 min
SEP 2
$TEVAMedAI 8/10

Teva Stock Drops As Celiac Trial Fails To Impress - TipRanks.com

Teva Pharmaceutical's (TEVA) stock declined despite early-stage positive results from a Phase 2a trial of TEV-408 for celiac disease. Investors were unimpressed due to the lack of later-stage data or a commercialization timeline. The company is focusing on specialty medicines and biosimilars to stabilize growth but faces challenges from debt and generic revenue pressure.

tipranks.com2 min
SEP 2
$TEVAMedAI 8/10

Teva Drug Rises to the Gluten Challenge, Stopping Intestinal Damage in Celiac Disease Trial

Teva Pharmaceutical Industries' experimental drug TEV-53408 met its main goal in a mid-stage trial, preventing intestinal damage in celiac disease patients. The Phase 2a study showed significant improvement in intestinal health and symptom scores compared to placebo. Teva plans further studies and projects peak sales of $1.5B-$2B for the drug, which targets the IL-15 pathway. The company has a deal with Royalty Pharma for up to $500M in support.

medcitynews.com2 min